chronic inflammatory demyelinating polyneuropathy cidp acquired autoimmune disease peripheral nervous system characterized progressive weakness impaired sensory function legs disorder sometimes called chronic relapsing polyneuropathy crp chronic inflammatory demyelinating polyradiculoneuropathy involves nerve cidp closely related syndrome considered chronic counterpart acute symptoms also similar progressive inflammatory neuropathy one several types neuropathy several variants reported specially important chronic inflammatory demyelinating polyneuropathy polyradiculoneuropathy considered autoimmune disorder destroying myelin protective covering nerves typical early symptoms tingling sort electrified vibration paresthesia numbness extremities frequent night leg cramps loss reflexes knees muscle fasciculations vibration feelings loss balance general muscle cramping nerve cidp extremely rare underrecognized undertreated due heterogeneous presentation clinical electrophysiological limitations clinical serologic electrophysiologic diagnostic criteria despite limitations early diagnosis treatment favoured preventing irreversible axonal loss improving functional lack awareness treatment cidp although stringent research criteria selecting patients clinical trials generally agreedupon clinical diagnostic criteria cidp due different presentations symptoms objective data application present research criteria routine clinical practice often misses diagnosis majority patients patients often left untreated despite progression cidp associated diabetes mellitus hiv infection paraproteinemiascitation needed variants cidp present autoimmunity proteins node ranvier variants comprise subgroup inflammatory neuropathies autoantibodies paranodal proteins cases special pathology also nonresponsive standard treatment responsive rituximab also cases combined central peripheral demyelination ccpd could produced autoantibodies components ranvier nodes specially autoantibodies contactinassociated protein caspr cause form cidp acute guillainbarrelike phase followed chronic phase progressive symptoms different igg subclasses associated different phases disease caspr autoantibodies found acute gbslike phase caspr autoantibodies present chronic phase diagnosis typically made basis presenting symptoms tandem electrodiagnostic testing nerve biopsy doctors may use lumbar puncture verify presence increased cerebrospinal fluid proteincitation needed cidp variants among several types immunemediated neuropathies include possible diagnoses reason diagnosis chronic inflammatory demyelinating polyneuropathy needs investigations diagnosis usually provisionally made clinical neurological examination symptoms diminished absent deeptendon reflexes sensory ataxia common symptoms include proximal distal muscle weakness limbscitation needed patients usually present history weakness numbness tingling pain difficulty walking may additionally present fainting spells standing burning pain extremities patients may sudden onset back pain neck pain radiating extremities usually diagnosed radicular pain symptoms usually progressive may intermittentcitation needed autonomic system dysfunction occur case patient would complain orthostatic dizziness problems breathing eye bowel bladder cardiac problems patient may also present single cranial nerve peripheral nerve dysfunctioncitation needed examination patients may weakness loss deep tendon reflexes rarely increased normal may atrophy shrinkage muscles fasciculations twitching loss sensation patients may multifocal motor neuropathy sensory losscitation needed experts consider necessary duration symptoms greater weeks diagnosis cidp made fatigue identified common cidp patients unclear much due primary due disease action body secondary effects impacts whole person ill typical diagnostic tests include cases electrophysiological studies fail show evidence demyelination though conventional electrophysiological diagnostic criteria met patient may still respond immunomodulatory treatments cases presence clinical characteristics suggestive cidp critical justifying full investigations including sural nerve firstline treatment cidp currently intravenous immunoglobulin treatments include corticosteroids eg prednisone plasmapheresis plasma exchange may prescribed alone combination immunosuppressant recent controlled studies show subcutaneous immunoglobulin appears effective cidp treatment intravenous immunoglobulin patients fewer systemic side intravenous immunoglobulin plasmapheresis proven benefit randomized doubleblind placebocontrolled trials despite less definitive published evidence efficacy corticosteroids considered standard therapies long history use cost effectiveness intravenous immunoglobulin probably firstline cidp treatment extremely expensive example us single g dose gamunex brand might billed rate including charges nurse administrationcitation needed immunosuppressive drugs often cytotoxic chemotherapy class including rituximab rituxan targets b cells cyclophosphamide drug reduces function immune system ciclosporin also used cidp less frequency newer ciclosporin thought bind immunocompetent lymphocytes especially tlymphocytescitation needed noncytotoxic immunosuppressive treatments usually include antirejection transplant drugs azathioprine imuranazoran mycophenolate mofetil cellcept us drugs used offlabel meaning indication treatment cidp package inserts azathioprine used patient first blood test ensures azathioprine safely usedcitation needed antithymocyte globulin immunosuppressive agent selectively destroys lymphocytes studied use cidp antithymocyte globulin gamma globulin fraction antiserum animals immunized human thymocytes polyclonal antibody although chemotherapeutic immunosuppressive agents shown effective treating cidp significant evidence lacking mostly due heterogeneous nature disease patient population addition lack controlled trialscitation needed review several treatments found azathioprine interferon alpha methotrexate cyclophosphamide rituximab seem response mycophenolate mofetil may use milder cases immunoglobulin steroids first line choices treatmentcitation needed severe cases cidp secondline immunomodulatory drugs efficient autologous hematopoietic stem cell transplantation hsct sometimes performed treatment may induce longterm remission even severe treatmentrefractory cases cidp improve outcome suggested initiated irreversible axonal damage occurred however precise estimation clinical efficacy cidp available randomized controlled trials rct ms astims rct provides evidence superior effect hsct thenbest practice treatment aggressive ms recent mist rct confirmed superiority physical therapy occupational therapy may improve muscle strength activities daily living mobility minimize shrinkage muscles tendons distortions joints multiple sclerosis another demyelinating condition possible predict certainty cidp affect patients time pattern relapses remissions varies greatly patient period relapse disturbing many patients make significant recoveriescitation needed diagnosed early initiation early treatment prevent loss nerve axons recommended however many individuals left residual numbness weakness tremors fatigue symptoms lead longterm morbidity diminished quality important build good relationship doctors primary care specialist rarity illness many doctors encountered case cidp different relapses occur may bring new symptoms problems variability severity progression disease doctors able give definite prognosis period experimentation different treatment regimens likely necessary order discover appropriate treatment regimen given patientcitation needed lewis et al reported group patients chronic asymmetrical sensorimotor neuropathy mostly affecting arms multifocal involvement peripheral also dyck et al reported response prednisolone condition referred chronic inflammatory demyelinating parry clarke described neuropathy later found associated igm autoantibodies directed latter condition later termed multifocal motor distinction important multifocal motor neuropathy responds intravenous immunoglobulin alone chronic inflammatory demyelinating polyneuropathy responds intravenous immunoglobulin steroids plasma suggested multifocal motor neuropathy distinct chronic inflammatory demyelinating polyneuropathy lewissumner syndrome distinct variant type chronic inflammatory demyelinating lewissumner form condition considered rare disease cases reported total cases reported national vaccine injury compensation program awarded money damages patients came cidp receiving one childhood vaccines listed federal governments vaccine injury table vaccine court awards often come language stating court denies specific vaccine caused petitioner suffer cidp injury nevertheless parties agree joint stipulation attached hereto appendix undersigned finds said stipulation reasonable adopts decision court awarding damages terms set forth keyword search court federal claims opinionsorders database term cidp returns opinions related cidp vaccine injury httpsenwikipediaorgwikichronicinflammatorydemyelinatingpolyneuropathy